Best Oncology Companies in Minnesota, United States

Developer of oncolytic-virus-based immunotherapies for cancer treatment. The company focuses on the development of new oncolytic virus treatments that leverage Vyriad’s vesicular stomatitis virus (VSV) platform, as well as antibody discovery capabilities. The company's lead product is Voyager-V1 which addresses multiple cancer types.

Developer of multi-phase prolonged release drug delivery platform for localized treatments. The company focuses on developing drug delivery solutions for pain, cancer, and infection treatments. It utilizes technology to address unmet needs in pain management and drug delivery markets. The company's products include an extended-release pain control solution focused on peri-operative pain management and an early-development product focused on local delivery of cancer drugs with a precise elution rate over a pre-programmed period of time.

Funding rounds

• Nov 2025Series A$4M
• Dec 2023Series A$3M
• Jun 2020Series A$5M
• Dec 2018Seed$2M

Founders & team

Bill TaylorCo-Founder & Chief Science OfficerDaniel SippleCo-Founder

Investors

Manhattan Street Fund, In5

Developer of a therapeutic solution to treat prostate, kidney, and bladder cancer. The company has developed a convective water vapor energy technology that is applied to deliver targeted treatments to the cancerous prostate tissue.

Developer of gene therapies for treating cancer. The company has developed a allogenic platform that utilizes gamma technology to develop a pipeline consists of two products LMY-920 for B-cell malignancies and autoimmune disorders, LMY-232 for solid tumors and autoimmune disorders.

Developer of precision imaging and radiation therapy for the treatment of cancer patients. The company provides cost-effective respiratory motion management alternatives, helping medical staff to treat and cure patients.

Funding rounds

• Nov 2025Series B$9.1M
• Sep 2023Series A$3.1M

Founders & team

Manojeet BhattacharyaFounder & CEO-EmpNia | University of Notre Dame PhD 1998

Developer of Sonodynamic therapy device for brain cancer. It offers a proprietary non-invasive treatment device that utilizes ultrasound to activate a drug targeting cancer cells for outpatient treatment of recurrent glioblastoma multiforme and selectively target and kill cancer cells.

Funding rounds

• May 2025Series B$52M
• Nov 2021Series A$16M

Founders & team

Vijay AgarwalFounder & CEO

Investors

Orbimed, Action Potential Venture Capital, BrightEdge, Brain Tumor Investment Fund, SV Health Investors, Health Quest Capital

Developer of precision combination therapies for cancer. It offers IDRX-42 and IDRX-73 small molecule tyrosine kinase inhibitors to inhibit the key genetic drivers and drug-resistant mutations of gastrointestinal stromal tumors.

Funding rounds

• Aug 2024Series B$120M
• Aug 2022Series A$122M

Founders & team

Nicholas LydonCo-FounderAlexis BorisyCo-Founder

Investors

RA Capital Management, Commodore Capital, Blackstone, Rock Springs Capital, Andreessen Horowitz, Casdin Capital

Provider of cell therapy research, patient support, and donor registry. They facilitate connections between researchers and supporters to accelerate innovation in finding cures. They maintain a registry of potential donors and work with transplant partners to expand access to treatment. The organization offers physical, emotional, spiritual, and financial support to patients and caregivers.

Developer of targeted therapies for cancer patients. Its platform CELx Pathway Profile analyzes disease-related metabolic pathways in ex vivo patient samples for drug response markers. Their flagship products have completed preclinical trials.

Humanetics Corporation is a clinical-stage biopharma company developing radiation modulators as therapeutics for solid cancers. Their lead candidate, BIO 300, is being developed as an agent to both sensitize tumor cells to enhance radiation treatment efficacy and to protect normal tissues from harm. The active in BIO300 is synthetic nanoparticle genistein, known to be a potent tyrosine kinase inhibitor (these kinases are often over-expressed in cancers). The company has received 4 grants from SBIR, of a total value of $1.12M. Humanetics has also received $8M in funding from the U.S. Department of Defense (DoD) to develop BIO 300 as a new medical radiation countermeasure (MRC) for lethal exposure to radiation.

Funding rounds

• Oct 2023Grant (prize money)—
• Sep 2023Grant (prize money)$298.5K
• Jul 2022Grant (prize money)$5.1M
• Jun 2021Grant (prize money)—

Founders & team

Ronald ZenkChief Executive Officer and member of the Board of Directors

Investors

Regenerative Medicine Minnesota, National Heart Lung and Blood Institute, Defense.gov, NIH, HHS, Military Health

Developer of thermal therapy for Benign Prostatic Hyperplasia(BPH). The Rezum System uses Radiofrequency energy to create sterile water vapor to address BPH by delivering targeted, controlled doses of stored thermal energy through heat convection directly to the region of the prostate gland that houses the obstructive tissue that causes BPH. The therapy can be used in an outpatient procedure.

Sweet Bonanza 1000: Exciting slot game with high winning opportunities. It is a vibrant online slot game offering an engaging and potentially rewarding experience. The game features a colorful theme centered around fruits and candies, creating a cheerful atmosphere for players. It is known for its innovative tumble mechanics, which allow for consecutive wins within a single spin. Multipliers further enhance the excitement and potential payouts. It provides high winning opportunities and an entertaining experience for those seeking a fun and potentially lucrative online game. It is a single product offering.